Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 15 of 27
A Study of LY2835219 in Healthy Participants
NCT02059148
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
NCT02072096
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
NCT02041091
A Study of Axiron® in Healthy Participants
NCT02004132
A Study of LY2928057 in Hemodialysis Participants
NCT01991483
A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes
NCT02020616
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
NCT02014116
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
NCT02009449
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
NCT01994746
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
NCT01925989
A Study of LY2801653 in Healthy Participants
NCT01981408
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
NCT01997411
A Study of LY2157299 in Healthy Participants
NCT01965808
A Study of LY3127760 in Healthy Participants
NCT01968070
A Study of [14C]-LY3023703 in Healthy Participants
NCT01965782
A Study of Tadalafil for Duchenne Muscular Dystrophy
NCT01865084
A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants
NCT01913314
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
NCT01900652
A Study of LY3050258 in Healthy Participants
NCT01929707
A Study of Evacetrapib and Digoxin in Healthy Participants
NCT01897493
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
NCT01893281
A Study of Evacetrapib and Rifampin in Healthy Participants
NCT01908582
A Study of Evacetrapib (LY2484595) in Healthy Participants
NCT01903434
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
NCT01900665
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
NCT01885078
A Study of Multiple Doses of LY2922470 in Participants With Diabetes
NCT01867216
A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal
NCT01872910
A Study of LY3015014 in Participants With High Cholesterol
NCT01890967
A Study of LY3025876 in Participants With Diabetes
NCT01870297
A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
NCT01870388
A Study of LY2605541 in Healthy Participants
NCT01877265
A Study of LY3002813 in Participants With Alzheimer's Disease
NCT01837641
A Multiple Dose Study of LY3023703 in Healthy Participants
NCT01849055
The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream
NCT01836198
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy
NCT01816295
A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
NCT01825889
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
NCT01836185
A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
NCT01825876
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
NCT01794000
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
NCT01788566
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes
NCT01790438
Study of LY3016859 in Participants With Diabetic Nephropathy
NCT01774981
A Study of LY2605541 in Healthy Participants and in the Elderly
NCT01818245
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
NCT01807026
Study of Food on Evacetrapib (LY2484595) in Healthy Participants
NCT01810432
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
NCT01777191
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
NCT01632306
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
NCT01774968
A Study of Two Dosage Forms of LY2886721 in Healthy Participants
NCT01775904
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
NCT01792284
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.